Table 2. Treatment characteristics of... | American Society of Hematology

Table 2.

Treatment characteristics of historical non-caplacizumab cohort vs caplacizumab cohort

	Non-caplacizumab cohort (n = 16), median (range)	Caplacizumab cohort (n = 17), median (range)	P value
Time from admission to PLEX initiation, d	0 (0-3)	1 (0-2)	.51
PLEX treatments	11 (5-42)	10 (4-19)	.74
Time from admission to steroid therapy, d	0 (0-7; n = 15)	0 (0-1; n = 17)	.19
Time from admission to rituximab therapy, d	5 (0-15; n = 13)	3 (1-7; n = 15)	.04
Patients receiving bortezomib, n (%)	2 (12.5)	1 (6.2)	.54
Time from admission to caplacizumab therapy, d	—	1 (0-4)	—
Caplacizumab doses	—	6 (2-30)∗	—
Total caplacizumab doses per UTSW approach∗	—	160∗	—
Total estimated drug cost per UTSW approach†	—	$1 521 600†	—
Estimated caplacizumab doses per manufacturer recommendations∗	—	840∗	—
Total estimated drug cost per manufacturer recommendations†	—	$7 988 400†	—

	Non-caplacizumab cohort (n = 16), median (range)	Caplacizumab cohort (n = 17), median (range)	P value
Time from admission to PLEX initiation, d	0 (0-3)	1 (0-2)	.51
PLEX treatments	11 (5-42)	10 (4-19)	.74
Time from admission to steroid therapy, d	0 (0-7; n = 15)	0 (0-1; n = 17)	.19
Time from admission to rituximab therapy, d	5 (0-15; n = 13)	3 (1-7; n = 15)	.04
Patients receiving bortezomib, n (%)	2 (12.5)	1 (6.2)	.54
Time from admission to caplacizumab therapy, d	—	1 (0-4)	—
Caplacizumab doses	—	6 (2-30)∗	—
Total caplacizumab doses per UTSW approach∗	—	160∗	—
Total estimated drug cost per UTSW approach†	—	$1 521 600†	—
Estimated caplacizumab doses per manufacturer recommendations∗	—	840∗	—
Total estimated drug cost per manufacturer recommendations†	—	$7 988 400†	—

UTSW, University of Texas Southwestern.

Value includes all iTTP episodes over the study observation period (n = 17).

Estimated cost based on reported wholesale price of $9510.